Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

被引：330

作者：

Knight, Steven D. ^{[1
]}

Adams, Nicholas D. ^{[1
]}

Burgess, JoeIle L. ^{[1
]}

Chaudhari, Amita M. ^{[1
]}

Darcy, Michael G. ^{[1
]}

Donatelli, Carla A. ^{[1
]}

Luengo, Juan I. ^{[1
]}

Newlander, Ken A. ^{[1
]}

Parrish, Cynthia A. ^{[1
]}

Ridgers, Lance H. ^{[1
]}

Sarpong, Martha A. ^{[1
]}

Schmidt, Stanley J. ^{[1
]}

Van Aller, Glenn S. ^{[1
]}

Carson, Jeffrey D. ^{[1
]}

Diamond, Melody A. ^{[1
]}

Elkins, Patricia A. ^{[1
]}

Gardiner, Christine M. ^{[1
]}

Garver, Eric ^{[1
]}

Gilbert, Seth A. ^{[1
]}

Gontarek, Richard R. ^{[1
]}

Jackson, Jeffrey R. ^{[1
]}

Kershner, Kevin L. ^{[1
]}

Luo, Lusong ^{[1
]}

Raha, Kaushik ^{[1
]}

Sherk, Christian S. ^{[1
]}

Sung, Chiu-Mei ^{[1
]}

Sutton, David ^{[1
]}

Tummino, Peter J. ^{[1
]}

Wegrzyn, Ronald J. ^{[1
]}

Auger, Kurt R. ^{[1
]}

Dhanak, Dashyant ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Collegeville, PA 19426 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2010年 / 1卷 / 01期

关键词：

GSK2126458; phosphoinositide 3-kinase alpha; mammalian target of rapamycin; PI3K/AKT pathway; CANCER-SPECIFIC MUTATIONS; PHOSPHATIDYLINOSITOL; 3-KINASES; PIK3CA; PHOSPHORYLATION; IDENTIFICATION; P110-ALPHA; PATHWAY; CELL;

D O I：

10.1021/ml900028r

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Phosphomositide 3-kinase alpha (PI3K alpha) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3K alpha and mTOR with in vivo activity in both pharrnacodynamic and tumor growth efficacy models Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.

引用

页码：39 / 43

页数：5

共 27 条

[1]

ADAMS ND, 2008, Patent No. 2008144463

[2]

ADAMS ND, 2008, Patent No. 2008144464

[3]

[Anonymous], EORTC NCI AACR INT C

[4] PDGF-DEPENDENT TYROSINE PHOSPHORYLATION STIMULATES PRODUCTION OF NOVEL POLYPHOSPHOINOSITIDES IN INTACT-CELLS [J].

AUGER, KR ;

SERUNIAN, LA ;

SOLTOFF, SP ;

LIBBY, P ;

CANTLEY, LC .

CELL, 1989, 57 (01) :167-175

[5] Cancer-specific mutations in PIK3CA are oncogenic in vivo [J].

Bader, AG ;

Kang, SY ;

Vogt, PK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1475-1479

[6] Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis [J].

Cully, M ;

You, H ;

Levine, AJ ;

Mak, TW .

NATURE REVIEWS CANCER, 2006, 6 (03) :184-192

[7]

Delano W.L., 2002, CCP4 NEWSL PROTEIN C, V4, P82

[8] The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism [J].

Engelman, Jeffrey A. ;

Luo, Ji ;

Cantley, Lewis C. .

NATURE REVIEWS GENETICS, 2006, 7 (08) :606-619

[9] The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer [J].

Folkes, Adrian J. ;

Ahmadi, Khatereh ;

Alderton, Wendy K. ;

Alix, Sonia ;

Baker, Stewart J. ;

Box, Gary ;

Chuckowree, Irina S. ;

Clarke, Paul A. ;

Depledge, Paul ;

Eccles, Suzanne A. ;

Friedman, Lori S. ;

Hayes, Angela ;

Hancox, Timothy C. ;

Kugendradas, Arumugam ;

Lensun, Letitia ;

Moore, Pauline ;

Olivero, Alan G. ;

Pang, Jodie ;

Patel, Sonal ;

Pergl-Wilson, Giles H. ;

Raynaud, Florence I. ;

Robson, Anthony ;

Saghir, Nahid ;

Salphati, Laurent ;

Sohal, Sukhjit ;

Ultsch, Mark H. ;

Valenti, Melanie ;

Wallweber, Heidi J. A. ;

Wan, Nan Chi ;

Wiesmann, Christian ;

Workman, Paul ;

Zhyvoloup, Alexander ;

Zvelebil, Marketa J. ;

Shuttleworth, Stephen J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (18) :5522-5532

[10] Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts [J].

Gray, A ;

Olsson, H ;

Batty, IH ;

Priganica, L ;

Downes, CP .

ANALYTICAL BIOCHEMISTRY, 2003, 313 (02) :234-245

← 1 2 3 →